Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

Condition

Wounds and Injuries

Interventions

Biological:LNA043

Other:Placebo

ClinicalTrials.gov identifier

NCT03275064

Novartis reference number

CLNA043X2202

Phase

Phase 2

This study is Recruiting.

Official title

A Two-part, Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 Injections in Regenerating the Articular Cartilage of the Knee in Patients With Articular Cartilage Lesions (Part A) and in Patients With Knee Osteoarthritis (Part B).

Purpose

The purpose of this two-part study is to assess the efficacy, safety and tolerability of multiple intra-articular (i.a.) injections of LNA043 in regenerating the articular surface in patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B).

Contacts and locations

Novartis contact

Novartis Pharmaceuticals 1-888-669-6682

Czechia

  • Novartis Investigative Site
    Brno, Czech Republic, Czechia, 66250
  • Novartis Investigative Site
    Mlada Boleslav, Czech Republic, Czechia, 29301
  • Novartis Investigative Site
    Kladno, Czechia, 272 59
  • Novartis Investigative Site
    Kolin, Czechia, 280 02
  • Novartis Investigative Site
    Pardubice, Czechia, 53002
  • Novartis Investigative Site
    Praha, Czechia

United States